ADVANTAN MILK nahaemulsioon Εσθονία - Εσθονικά - Ravimiamet

advantan milk nahaemulsioon

leo pharma a/s - metüülprednisoloonatseponaat - nahaemulsioon - 1mg 1g 50g 1tk; 1mg 1g 20g 1tk

ADVANTAN MILK nahaemulsioon Εσθονία - Εσθονικά - Ravimiamet

advantan milk nahaemulsioon

ideal trade links uab - metüülprednisoloonatseponaat - nahaemulsioon - 1mg 1g 50g 1tk; 1mg 1g 20g 1tk

Coxevac Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

coxevac

ceva santé animale - inaktiveeritud coxiella burnetii vaktsiin, üheksa miili tüvi - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

MAGVIT B6 gastroresistentne tablett Εσθονία - Εσθονικά - Ravimiamet

magvit b6 gastroresistentne tablett

richard bittner ag - püridoksiin+magneesium - gastroresistentne tablett - 5mg+470mg 30tk; 5mg+470mg 50tk

Calciject PMD süstelahus Εσθονία - Εσθονικά - Ravimiamet

calciject pmd süstelahus

norbrook laboratories limited - kaltsiumglükonaat+boorhape+glükoos+magneesiumhüpofosfit - süstelahus - 166mg+34mg+220mg+50mg 1ml 400ml 1tk

Lydisilka Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

lydisilka

estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - suguhormoonid ja genitaalsüsteemi, - suukaudne kontratseptsioon. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.

OLMESARTAN MEDOXOMIL/AMLODIPINE ZENTIVA õhukese polümeerikattega tablett Εσθονία - Εσθονικά - Ravimiamet

olmesartan medoxomil/amlodipine zentiva õhukese polümeerikattega tablett

zentiva k.s. - olmesartaanmedoksomiil+amlodipiin - õhukese polümeerikattega tablett - 40mg+5mg 98tk; 40mg+5mg 30tk; 40mg+5mg 14tk; 40mg+5mg 90tk; 40mg+5mg 56tk; 40mg+5mg 28tk

OLMESARTAN MEDOXOMIL/HCT SIGILLATA õhukese polümeerikattega tablett Εσθονία - Εσθονικά - Ravimiamet

olmesartan medoxomil/hct sigillata õhukese polümeerikattega tablett

sigillata limited - olmesartaanmedoksomiil+hüdroklorotiasiid - õhukese polümeerikattega tablett - 40mg+25mg 90tk; 40mg+25mg 98tk; 40mg+25mg 14tk; 40mg+25mg 30tk; 40mg+25mg 28tk